VVOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vivos Therapeutics Inc (VVOS) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is currently in a bearish trend with no positive technical or fundamental indicators to support a buy decision. Analysts have lowered price targets significantly, citing weak financial performance, potential share dilution, and operational inefficiencies. Additionally, there are no recent positive catalysts or trading signals to suggest a reversal in the stock's trajectory.
The technical indicators for VVOS are bearish. The MACD is negatively expanding, RSI is neutral at 23.679, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 0.469 and S2 at 0.254, indicating further downside potential.
NULL identified. No recent news or events suggest any positive momentum for the stock.
Analysts have lowered price targets significantly, citing weak Q4 results, missed revenue expectations, higher expenses, and potential share dilution. The stock is also in a bearish technical trend with no signs of reversal.
No financial data available for detailed analysis. However, analysts have reported weak Q4 results with missed revenue expectations and higher expenses, suggesting poor financial performance.
Analysts have lowered price targets significantly. H.C. Wainwright reduced the target from $7 to $2.50, maintaining a Buy rating but expressing concerns about share dilution and operational inefficiencies. Alliance Global lowered the target from $2.50 to $1.75 and gave a Neutral rating, citing weak Q4 results and the need for balance sheet strengthening.
